Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature
|Authors:||Blake, J., Brooks, J., Greenbaum, H., Chan, F.|
|Publication||Expert Opinion on Pharmacotherapy|
Rheumatoid arthritis causes pain and serious functional impacts and substantially affects patients' daily lives, including their ability to work.
The purpose of the paper is to examine recent studies of patients with Rheumatoid Arthritis treated with TNF antagonists and the impacts these therapies have on the workplace.
This study is a systematic review. The included studies were undertaken in various locations and settings.
The sample included 133 articles and 14 poster abstracts that studied the impact of Rheumatoid Arthritis.
The studies were categorized into three distinct groups: general RA, DMARD, and TNF-antagonist literature. The general RA literature was used as a backdrop when examining literature regarding the impacts of DMARDs and the emergence of anti-TNF therapies on the workplace.
There were no comparison or control conditions.
The results of early studies of the TNF antagonists varied regarding their effects on patients with RA in the workplace. Recent studies of adalimumab showed positive impacts across a range of workplace burdens.
Treatments such as adalimumab may help employees with RA to remain in the workforce and lead to reduced workplace costs to the employers and employees.
|Populations||Male & Female|
|Outcomes||Employment acquisition | Increase in tenure|
|Research Design||Systematic reviews and meta-analysis|